Silence Therapeutics plc (SLN) Tops Q1 EPS by 3c

Silence Therapeutics plc (NASDAQ: SLN) reported Q1 EPS of ($0.11), $0.03 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $400 thousand versus the consensus estimate of $1.32 million.

For earnings history and earnings-related data on Silence Therapeutics plc (SLN) click here.

You May Also Be Interested In

• Anthropic plans IPO potentially exceeding SpaceX's $86B record - Bloomberg
• Leggett & Platt shareholders approve merger with Somnigroup
• Meritage Homes Corporation (MTH) Declares $0.48 Quarterly Dividend; 2.7% Yield